Corporate Info
Smart Quotes
Company Background
Board of Directors
Balance Sheet
Profit & Loss
Peer Comparison
Cash Flow
Shareholdings Pattern
Quarterly Results
Share Price
Deliverable Volume
Historical Volume
MF Holdings
Financial Ratios
Directors Report
Price Charts
Notes Of Account
Management Discussion
Beta Analysis
Board Meetings
Corporate Announcements
Book Closure
Record Date
Bonus
Company News
Bulk Deals
Block Deals
Monthly High/low
Dividend Details
Bulk Deals
Insider Trading
Advanced Chart
HOME   >  CORPORATE INFO >  COMPANY NEWS
Company News      
Alkem Laboratories Ltd.
Change Company   
BSE Code 539523
ISIN Demat INE540L01014
Book Value 1194.91
NSE Code ALKEM
Dividend Yield % 0.82
Market Cap 652227.08
P/E 29.73
EPS 183.49
Face Value 2  
09-May-2026 USFDA completes inspection at Alkem Laboratories’...
13-Apr-2026 Alkem Laboratories incorporates wholly owned subs...
13-Apr-2026 Alkem Laboratories informs about updates
07-Apr-2026 Alkem Laboratories launches everyday multivitamin...
31-Mar-2026 Alkem Laboratories incorporates subsidiary in Dub...
23-Mar-2026 Alkem Laboratories launches semaglutide injection...
21-Mar-2026 Alkem Laboratories informs about press release
21-Mar-2026 Alkem Laboratories informs about updates
16-Mar-2026 Alkem Laboratories gets certificate of GMP Compli...
16-Feb-2026 Alkem Laboratories reports marginal rise in Q3 co...
16-Feb-2026 Alkem Laboratories gains on reporting marginal ri...
14-Feb-2026 USFDA completes pre-approval inspection of manufa...
13-Feb-2026 Alkem Laboratories’ arm to acquire majority stake...
12-Feb-2026 Alkem Laboratories informs about conference call
12-Feb-2026 Alkem Laboratories informs about conference call
Page 1 of 3
Prev || Next
Disclaimer | Privacy Policy | Grievance | FAQ | Sitemap | Client Registration | Useful Links| Anti Money Laundering | Inactive Client Policy | Scores
Smart ODR Portal | Vernacular Kyc | Advisory For Investors | Investor Adviser | Filing complaints on SCORES - Easy & quick | Policy on PMLA | Publishing of investor charter information | Annexure A – Investor charter of brokers | Annexure A – Investor charter of DP | Annexure B –Linked content for information to charter for DP | Annexure B & C (investor complaint data) broker & DP | Investor Charter & Complaints | Advisory-KYC Compliance | E-Voting NSE | E-Voting BSE | Details of Client Bank Accounts | Risk Disclosure | NSE FO Risk disclosure | Details of Research Analyst | UPI QR CODE
SEBI Regn. No.: INB010997431 (BSE), INB230997430 (NSE)
Copyright 2008 Javeri Fiscal Services Ltd.
Designed , Developed & Content Powered by Accord Fintech Pvt. Ltd.
CLOSE X

RISK DISCLOSURES ON DERIVATIVES

  • 9 out of 10 individual traders in equity Futures and Options Segment, incurred net losses.
  • On an average, loss makers registered net trading loss close to ₹ 50,000.
  • Over and above the net trading losses incurred, loss makers expended an additional 28% of net trading losses as transaction costs.
  • Those making net trading profits, incurred between 15% to 50% of such profits as transaction cost.
Source: Click Here.